Amerise is a global research and innovation-driven Integrated pharmaceutical company focusing on the NDA, 505(B)(2), and complex formulations.
Core expertise includes development of injectables, ophthalmics, and oral dosage forms from ‘Concept to clinic‘.
Established in 2018 with an aim to contribute towards the well-being and improving the health of people around the globe through the provision of innovative and reliable pharmaceutical products and services.
Amerise Pharma offers proven expertise in providing regulatory-compliant support for development of 505(b)(2) products and filing support for Generic products which includes: pre-IND meeting with FDA, IND-enabling studies, product registation and management of clinical services
To become a global recognized as domestic and internationally integrated pharmaceutical company through Innovation, Quality and Competence.
To be a globally admired, innovative, well recognized, best-in-class reputable pharmaceutical company. Amerise will seek to enhance its enterprise value in a sustainable manner with top quality management.
Ready to use stable liquid herbal composition
Priority date : 30-Sep-20
Anti-vertigo compound and pharmaceutical compositions
Priority date : 20-Oct-20
Stable pharmaceutical composition of non-steroidal antiandrogens
Priority date : 15-Nov-21
Oral Pharmaceutical Composition
Priority date : 1-Sep-22